32 results on '"Myelodysplastic syndromes -- Patient outcomes"'
Search Results
2. Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS)
3. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study
4. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
5. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes
6. Cause of death in patients with lower-risk myelodysplastic syndrome
7. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program
8. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome
9. The heterogenous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
10. Mental status changes after hematopoietic stem cell transplantation
11. An assessment of erythroid response to epoetin (alpha) as a single agent versus in combination with granulocyte- or granulocyte-macrophage - colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach
12. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)
13. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
14. Myelodysplastic syndromes: incidence and survival in the United States
15. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
16. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life
17. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
18. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
19. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
20. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
21. Studies from Data Center and Health Outcomes Research Unit Further Understanding of Myelodysplastic Syndromes (High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity)
22. New Findings in Myelodysplastic Syndromes Described from University of Tokyo (Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation)
23. Janssen Global Services LLC Researchers Focus on Myelodysplastic Syndromes (Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes)
24. HIV and myelodysplasia
25. VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network (NCCN) in Its Clinical Practice Guidelines
26. Landmark Study Published in The Lancet Oncology Shows Celgene's Vidaza[R] Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia
27. New Analysis Shows that VIDAZA Prolongs Survival in Patients with Higher-Risk Myelodysplastic Syndromes
28. Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
29. Transplantation for Older Adults with AML and MDS
30. VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network NCCN in Its Clinical Practice Guidelines
31. Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients with Myelodysplastic Syndromes (MDS)
32. Could Melphalan be Useful for Elderly Patients with Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.